KCT-01（一种抗乙型肝炎病毒的新草药配方）的体外和体内抗

StephenW

Evid Based Complement Alternat Med. 2018 Jul 4;2018:1073509. doi: 10.1155/2018/1073509. eCollection 2018.
Preclinical Evaluation of In Vitro and In Vivo Antiviral Activities of KCT-01, a New Herbal Formula against Hepatitis B Virus.
Kim H1, Jang E2,3, Kim SY4, Choi JY4, Lee NR4, Kim DS5, Lee KT6,7, Inn KS4, Kim BJ1, Lee JH2.
Author information

1
    Department of Microbiology and Immunology, Liver Research Institute, Cancer Research Institute and SNUMRC, College of Medicine, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
2
    Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
3
    Department of Internal Medicine, Kyung Hee University Korean Medicine Hospital, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
4
    Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
5
    Hanpoon Pharmacy Company Limited, 301, Wanjusandan 6-ro, Bongdong-eup, Wanju Gun, Jeollabuk-do 55316, Republic of Korea.
6
    Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
7
    Department of Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.

Abstract

Hepatitis B virus (HBV) infectious diseases currently remain incurable due to limitations of conventional antivirals such as incapability of eradicating HBV DNA, prolonged use, drug resistance, and virological relapse. KCT-01, a 30% ethanol extract consisting of Artemisia capillaris, Sanguisorba officinalis, and Curcuma longa, was newly developed. The objective of this study was to investigate pharmacological activities of KCT-01 against HBV using HepG2.2.15 cells and a hydrodynamic injection model. KCT-01 significantly lowered antigen secretion, virion production, and pgRNA synthesis in HepG2.2.15 cells without affecting cell viability. KCT-01 administration also resulted in significant decrease of serum virion production, liver covalently closed circular (ccc) DNA levels, and mRNA synthesis of cytokines in the liver of mice injected with HBV DNA hydrodynamically. Interestingly, coadministration of KCT-01 with entecavir enhanced its in vitro and in vivo antiviral activities. Moreover, safety of KCT-01 was assured up to 5000 mg/kg in rats in both single and repeated-dose preclinical studies. Taken together, our findings demonstrate that KCT-01 is capable of suppressing HBV replication and inflammatory cytokine production in in vitro and in vivo models without showing toxicity, suggesting the potential of using KCT-01 alone or in combination with entecavir as antiviral agent.

PMID:
    30069220
PMCID:
    PMC6057320
DOI:
    10.1155/2018/1073509

StephenW

基于Evid的补充Alternat Med。 2018年7月4日; 2018年：1073509。 doi：10.1155 / 2018/1073509。 eCollection 2018。
KCT-01（一种抗乙型肝炎病毒的新草药配方）的体外和体内抗病毒活性的临床前评估。
Kim H1，Jang E2,3，Kim SY4，Choi JY4，Lee NR4，Kim DS5，Lee KT6,7，Inn KS4，Kim BJ1，Lee JH2。
作者信息

1
    首尔国立大学医学院肝脏研究所微生物学与免疫学系，SNUMRC，韩国首尔钟路区大邱路103号，03080。
2
    韩国首尔东大门区Kyungheedae-26，庆熙大学韩国医学院内科，02447，韩国
3
    韩国首尔东大门区Kyungheedae-ro 23 Kyung Hee University Korean Medicine Hospital内科，02447，韩国。
4
    韩国首尔东大门区Kyungheedae-ro 26，Kyung Hee University研究生院基础药学系，02447。
五
    Hanpoon Pharmacy Company Limited，301，Wanjusandan 6-ro，Bongdong-eup，Wanju Gun，Jeollabuk-do 55316，大韩民国。
6
    庆熙大学药学院药物生物化学系，韩国首尔东大门区Kyungheedae-ro 26号，02447。
7
    韩国首尔东大门区Kyungheedae-26，庆熙大学药学院生命与纳米制药科学系，02447，韩国。

抽象

由于常规抗病毒药物的局限性，例如无法根除HBV DNA，长期使用，耐药性和病毒学复发，目前乙型肝炎病毒（HBV）传染病仍然无法治愈。 KCT-01是一种30％的乙醇提取物，由茵陈蒿，Sanguisorba officinalis和Curcuma longa组成，是新开发的。本研究的目的是使用HepG2.2.15细胞和流体动力学注射模型研究KCT-01对HBV的药理活性。 KCT-01显着降低HepG2.2.15细胞中的抗原分泌，病毒粒子产生和pgRNA合成，而不影响细胞活力。 KCT-01施用还导致血液动力学注射HBV DNA的小鼠肝脏中血清病毒粒子产生，肝脏共价闭合环状（ccc）DNA水平和细胞因子mRNA合成的显着降低。有趣的是，KCT-01与恩替卡韦的共同给药增强了其体外和体内抗病毒活性。此外，在单次和重复剂量的临床前研究中，KCT-01的安全性在大鼠中确保高达5000mg / kg。总之，我们的研究结果表明，KCT-01能够在体外和体内模型中抑制HBV复制和炎性细胞因子的产生而不显示毒性，表明单独使用KCT-01或与恩替卡韦联合使用作为抗病毒剂的潜力。

结论：
    30069220
PMCID：
    PMC6057320
DOI：
    10.1155 /一百〇七万三千五百〇九分之二千〇一十八

MP4

茵陈

地榆

姜黄